Anlon Healthcare manufactures Active Pharmaceutical Ingredients & intermediates, supplying to both domestic and international markets. The issue size of the IPO is ₹121.03 crore with all being as book-built fresh issue and no OFS , the price range for the IPO is ₹86–₹91 per share.
Anlon Healthcare is open for subscription from 26th Aug’25 and closes on 29nd Aug’25. The price band is ₹ 86 to ₹ 91/share with the lot size of 164 shares, aggregating to minimum investment for retail investors to ₹ 14,924 considering the upper band.
| Year | 2025 |
| Networth | ₹80.42 Cr |
| Revenue: | ₹120.4 Cr |
| EBITDA | ₹32.3 Cr |
| PAT | ₹20.52 Cr |
| EBITDA Margin: | 26.90% |
| PAT Margin | 17.00% |
Anlon Healthcare Ltd Financials (Consolidated Figures)
| Year (Approx Values) | Revenue (₹ Cr) | Profit (₹ Cr) | Assets (₹ Cr) | Borrowings (₹ Cr) | Net Worth (₹ Cr) |
| 2023 | 113 | 5.8 | 111.5 | 66.3 | 7.3 |
| 2024 | 66.6 | 9.6 | 128 | 74.5 | 21 |
| 2025 | 120.3 | 20.5 | 181.3 | 58.3 | 80.4 |
Core Offerings & Store location of Anlon Healthcare
Founded in 2013.
Mr. Punitkumar R. Rasadia (Chairman & Managing Director)
Anlon Healthcare is a specialty chemicals and pharmaceutical company engaged mainly in manufacturing & supply of Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates, neutraceutical ingredients, personal-care ingredients. It is one of the few Indian companies to develop and supply Loxoprofen Sodium Dihydrate (a widely used anti-inflammatory and analgesic drug API)
Anlon Healthcare has a single manufacturing facility which is located in Gujarat, India. This state-of-the-art manufacturing unit has advanced in-house R&D and quality control laboratories.
Anlon Healthcare IPO Strengths & Risks
Strengths:
> Diverse product basket (65 commercial, 28 at pilot stage & 49 products undergoing laboratory-scale testing. strong pipeline of pilot/lab products)
> Global regulatory presence, DMF approvals from international regulators Brazil (ANVISA), China(NMPA), and Japan(PMDA) supporting exports
> In-house QC/QA & labs, focus on QEHS. Two dedicated manufacturing blocks
> Dedicated API & intermediate blocks with 400 MT per annum installed capacity. Along with filtration, centrifugation & drying systems
> Experienced promoter/management team with domain expertise
Risks:
> Strict audits & inspections by regulatories & customers any audit failures or issues can hit business.
> Revenue concentration in top clients (~77% from top 10 customers), any disruptions in contract renewal, negotiations can impact it.
> High debt-equity ratio (0.73), negative cashflow in each year.
> Regulatory/approval timelines can delay product commercialization.
> Fluctuations is revenue as its saw a big dip in year 2024
Anlon Healthcare: IPO date & invest detail
| IPO Open Date: | 26 August 2025 |
| IPO Close Date: | 29 August 2025 |
| Anchor Investor Bidding | 25 August 2025 |
| IPO Allotment Date: | 01 September 2025 |
| Refunds & Demat Credit | 02 September 2025 |
| Tentative Listing Date: | 03 September 2025 |
| IPO Category | ENTERPRISE |
| Symbol | ANLONHEALT |
| Face Value: | Rs.10 per Equity Share |
| Issue Size: | ~₹121 crore |
| Lot Size: | 164 shares per lot and multiples thereof |
Anlon Healthcare Composition & Proceeds
| Fresh Issue: | ~1.33 Cr shares |
| Offer for Sale: | 0 |
| Employee reservation | Nil |
| Price Range | ₹ 86- ₹91 per share |
| Face Value: | ₹ 10 |
| Debt Repayment | ₹ 5 Crore |
| Working Capital | ₹ 43.15 Crore |
| Facility Expansion | ₹ 30.72 Crore |
| General corporate purpose | Balance |
| IPO Listing on: | NSE & BSE |
| Retail Quota: | ≥ 35% |
| QIB Quota: | ≤ 50% |
| NII Quota: | ≥ 15% |
| Application Type | Lot Size | No. of Lots | No. of Shares | Investment Amount |
| Retail(Min) | 164 | 1 | 164 | 14,924 |
| Retail (Max) | 164 | 13 | 2,132 | 1,94,012 |
| Small HNI (Min) | 164 | 14 | 2,296 | 2,08,936 |
| Small HNI (Max) | 164 | 66 | 10,824 | 9,84,984 |
| Big HNI (Min) | 164 | 67 | 10,988 | 9,99,908 |
Anlon Healthcare Grey market premium
| Date | IPO Price | IPO GMP | GMP Trend | Estimated listing | Estimated profit |
| 29-Aug | – | – | – | – | – |
| 28-Aug | ₹ 91 | ₹ 6 | Positive | ₹ 97 | ₹ 984 |
| 27-Aug | ₹ 91 | ₹ 6 | Positive | ₹ 97 | ₹ 984 |
| 26-Aug | ₹ 91 | ₹ 5 | Positive | ₹ 96 | ₹ 820 |
| 25-Aug | ₹ 91 | ₹ 5 | Positive | ₹ 96 | ₹ 820 |
| 24-Aug | ₹ 91 | – | Positive | – | – |
| 23-Aug | ₹ 91 | – | Positive | – | – |
Promoters – Pre offer equity (Approx)
Punitkumar R. Rasadia
Meet Atulkumar Vachhani
Mamata Punitkumar Rasadia
To visit Anlon Healthcare official website click here
For more upcoming IPO’s click here